person · Reporting owner

EASTLAND JULIA MARIE

Disclosed activity across 6 companies

Tapewire entity: 46440
SEC CIK: 0001500189

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CalciMedica, Inc.GRAY · Entity 7804	Director	March 23, 2023	March 27, 2023
DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930	Director	May 23, 2024	May 28, 2024
Lantheus Holdings, Inc.LNTH · Entity 690	Director	May 14, 2026	May 18, 2026
Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772	Director · CEO & President	February 06, 2026	February 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CalciMedica, Inc.

Report date March 23, 2023 · Filed March 27, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,429	Reported balance After 2023-03-23 transaction · row 1 1 source row Row 1 · 2023-03-23 · Disposition to issuer · Acquired 1,429 · Balance 1,429 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-03-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-23 · Disposition to issuer · Disposed 1,429 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

DYNAVAX TECHNOLOGIES CORP

Report date May 23, 2024 · Filed May 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,071	Reported balance After 2024-05-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-05-23 · Grant · Acquired 5,357 · Balance 16,071 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-05-22	Direct	22,500	Reported balance After 2024-05-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-23 · Grant · Acquired 22,500 · Balance 22,500 F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.

F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Lantheus Holdings, Inc.

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,019	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 8,019

Zentalis Pharmaceuticals, Inc.

Report date February 06, 2026 · Filed February 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	79,133	Ending reported balance After 2026-02-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-06 · Sale · Disposed 7,866 · Balance 80,022 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Row 2 · 2026-02-09 · Sale · Disposed 889 · Balance 79,133 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cascadian Therapeutics, Inc.

Report date March 09, 2018 · Filed March 13, 2018

Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-03-09 transaction · row 1 1 source row Row 1 · 2018-03-09 · Other · Disposed 5,237 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.86 · Expires 2018-11-10	Direct	Reported balance After 2018-03-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-09 · Disposition to issuer · Disposed 6,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.92 · Expires 2018-12-01	Direct	Reported balance After 2018-03-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.52 · Expires 2019-12-01	Direct	Reported balance After 2018-03-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F5: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.44 · Expires 2020-12-12	Direct	Reported balance After 2018-03-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2021-12-12	Direct	Reported balance After 2018-03-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-03-09 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F7: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2022-12-16	Direct	Reported balance After 2018-03-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-03-09 · Disposition to issuer · Disposed 16,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F8: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2023-09-24	Direct	Reported balance After 2018-03-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-03-09 · Disposition to issuer · Disposed 41,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F9: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2024-05-17	Direct	Reported balance After 2018-03-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-03-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F11: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F10: 25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-01-11	Direct	Reported balance After 2018-03-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-03-09 · Disposition to issuer · Disposed 51,200 · Balance 0 F13: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F12: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2027-09-18	Direct	Reported balance After 2018-03-09 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-03-09 · Disposition to issuer · Disposed 75,000 · Balance 0 F15: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F14: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-09 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-03-09 · Disposition to issuer · Disposed 11,300 · Balance 0 F16: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F17: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-09 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-03-09 · Disposition to issuer · Disposed 16,500 · Balance 0 F19: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F20: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-09 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-03-09 · Disposition to issuer · Disposed 199,000 · Balance 0 F21: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F22: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.

F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months.

F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price.

F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months.

F5: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months.

F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months.

F7: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months.

F8: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months.

F9: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months.

F10: 25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months.

F11: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.

F12: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months.

F13: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.

F14: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months.

F15: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.

F16: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F17: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.

F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

F19: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F20: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.

F21: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F22: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years.

Harpoon Therapeutics, Inc.

Report date March 11, 2024 · Filed March 11, 2024

Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	269,381	Reported balance After 2024-03-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-11 · Grant · Acquired 31,250 · Balance 269,381 F1: Reflects the number of restricted stock units ("RSUs") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), issuable upon the vesting of RSUs. F2: Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-03-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-03-11 · Disposition to issuer · Disposed 269,381 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F4: Includes 259,750 RSUs. F5: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15	Direct	0	Reported balance After 2024-03-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-11 · Disposition to issuer · Disposed 2,765 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.90	Direct	0	Reported balance After 2024-03-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-11 · Disposition to issuer · Disposed 40,759 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the number of restricted stock units ("RSUs") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), issuable upon the vesting of RSUs.

F2: Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024.

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Includes 259,750 RSUs.

F5: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").

F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the

F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2026 Filed May 18, 2026 16:34 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	4,137	$0.00	$0.00	Disclosure SEC source: 0002064832-26-000203 · form4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,019 Read SEC document
February 09, 2026 Filed Feb 11, 2026 02:09 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	SaleCommon Stock	889	$2.39	$2,127.29	Disclosure SEC source: 0001500189-26-000004 · wk-form4_1770775778.xml · nonDerivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,133 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document
February 06, 2026 Filed Feb 11, 2026 02:09 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	SaleCommon Stock	7,866	$2.43	$19,112.02	Disclosure SEC source: 0001500189-26-000004 · wk-form4_1770775778.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,022 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document
January 08, 2026 Filed Jan 10, 2026 01:33 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	GrantStock Option (Right to Buy) · Derivative	775,000	$0.00 Strike: $2.84	$0.00	Disclosure SEC source: 0001500189-26-000002 · wk-form4_1768008785.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 775,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 14, 2025 Filed May 16, 2025 16:39 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	4,543	$0.00 Strike: $78.81	$0.00	Disclosure SEC source: 0001062993-25-009692 · form4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document
May 14, 2025 Filed May 16, 2025 16:39 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	2,537	$0.00	$0.00	Disclosure SEC source: 0001062993-25-009692 · form4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,882 Read SEC document
February 03, 2025 Filed Feb 5, 2025 23:29 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	GrantStock Option (Right to Buy) · Derivative	59,388	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001725160-25-000036 · wk-form4_1738798191.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,388 Underlying: Common Stock · 59,388 shares Expires 2035-02-02 F2 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document
February 03, 2025 Filed Feb 5, 2025 23:29 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	GrantCommon Stock	59,388	$0.00	$0.00	Disclosure SEC source: 0001725160-25-000036 · wk-form4_1738798191.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,888 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document
January 31, 2025 Filed Feb 4, 2025 21:37 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	PurchaseCommon Stock	28,500	$1.73	$49,344.90	Disclosure SEC source: 0001725160-25-000028 · wk-form4_1738705022.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Read SEC document
December 02, 2024 Filed Dec 4, 2024 00:02 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	GrantStock Option (Right to Buy) · Derivative	3,028,800	$0.00 Strike: $3.66	$0.00	Disclosure SEC source: 0001725160-24-000189 · wk-form4_1733270528.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,028,800 Underlying: Common Stock · 3,028,800 shares Expires 2034-12-02 F1 · derivative.exercise_date: The options will vest over a four-year period following the vesting commencement date of November 13, 2024, in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document
September 10, 2024 Filed Sep 12, 2024 17:57 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	2,506	$0.00 Strike: $99.08	$0.00	Disclosure SEC source: 0001062993-24-016538 · form4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,506 Underlying: Common Stock · 2,506 shares Expires 2034-09-10 Read SEC document
September 10, 2024 Filed Sep 12, 2024 17:57 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	1,345	$0.00	$0.00	Disclosure SEC source: 0001062993-24-016538 · form4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,345 Read SEC document
May 23, 2024 Filed May 28, 2024 20:30 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0000950170-24-065588 · ownership.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-22 F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document
May 23, 2024 Filed May 28, 2024 20:30 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantCommon Stock	5,357	$0.00	$0.00	Disclosure SEC source: 0000950170-24-065588 · ownership.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,071 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. Read SEC document
March 11, 2024 Filed Mar 11, 2024 17:17 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	40,759	Not disclosed Strike: $8.90	Not disclosed	Disclosure SEC source: 0000950170-24-029430 · ownership.xml · derivative · entry 4 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,759 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · price: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · derivative.exercise_date: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · derivative.expiration_date: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document
March 11, 2024 Filed Mar 11, 2024 17:17 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	2,765	Not disclosed Strike: $21.15	Not disclosed	Disclosure SEC source: 0000950170-24-029430 · ownership.xml · derivative · entry 3 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,765 shares Expires not disclosed F3 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · price: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · derivative.exercise_date: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8 · derivative.expiration_date: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document
March 11, 2024 Filed Mar 11, 2024 17:17 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	Disposition to issuerCommon Stock	269,381	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-029430 · ownership.xml · nonDerivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F4 · shares: Includes 259,750 RSUs. F5 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). F3 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document
March 11, 2024 Filed Mar 11, 2024 17:17 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantCommon Stock	31,250	$0.00	$0.00	Disclosure SEC source: 0000950170-24-029430 · ownership.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,381 F1 · kind: Reflects the number of restricted stock units ("RSUs") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), issuable upon the vesting of RSUs. F2 · balance_after: Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024. Read SEC document
January 07, 2024 Filed Jan 9, 2024 16:30 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantCommon Stock	178,500	$0.00	$0.00	Disclosure SEC source: 0000950170-24-003365 · ownership.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,003 F1 · shares: The grant of restricted stock units ("RSUs") to the Reporting Person as reported herein was approved by the Issuer's Compensation Committee on January 7, 2024 ("Grant Date") as part of the Issuer's annual grant of equity awards in the ordinary course. Each RSU represents a contingent right to receive one share of the Issuer's common stock, issuable upon the vesting and settlement of RSUs. F2 · shares: The RSUs vest quarterly over four years from the Grant Date, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
November 26, 2023 Filed Nov 28, 2023 16:30 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-056805 · doc4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,503 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, issuable upon the vesting and settlement of RSUs. F2 · shares: 25% of the RSUs will vest on each May 26th and November 26th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: Includes 500 shares acquired under the Issuer's employee stock purchase plan on September 30, 2022, 750 shares acquired on March 31, 2023, and 2,253 shares acquired on September 29, 2023. F4 · balance_after: Shares reflect 1:10 reverse stock split effective September 1, 2023. Read SEC document
May 26, 2023 Filed May 31, 2023 17:23 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $11.20	$0.00	Disclosure SEC source: 0001209191-23-033162 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document
May 26, 2023 Filed May 31, 2023 17:23 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantCommon Stock	5,357	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033162 · doc4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,714 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. The reporting person has reported prior awards of restricted stock units in Table II on Form 4. The total reported in Column 5 includes 5,357 newly awarded restricted stock units and 5,357 restricted stock units previously reported in Table II. Read SEC document
March 23, 2023 Filed Mar 27, 2023 19:57 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerRestricted Stock Unit · Derivative	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021301 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 23, 2023 Filed Mar 27, 2023 19:57 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerCommon Stock	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021301 · doc4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
January 24, 2023 Filed Jan 26, 2023 16:05 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantEmployee Stock Option (right to buy) · Derivative	407,600	$0.00 Strike: $0.89	$0.00	Disclosure SEC source: 0001209191-23-005030 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,600 Underlying: Common Stock · 407,600 shares Expires 2033-01-23 F1 · derivative.exercise_date: 1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the "VCD"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 17:35 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034256 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, subject to the reporting person's continued status as a service provider to the issuer. F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 17:35 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.98	$0.00	Disclosure SEC source: 0001209191-22-034256 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
May 26, 2022 Filed May 27, 2022 17:01 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantOption (Right to Buy) · Derivative	22,500	Not disclosed Strike: $11.68	Not disclosed	Disclosure SEC source: 0001209191-22-032616 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-25 F3 · price: Not applicable. F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document
May 26, 2022 Filed May 27, 2022 17:01 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantRestricted Stock Unit · Derivative	5,357	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-032616 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Underlying: Common Stock · 5,357 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. Read SEC document
November 08, 2021 Filed Nov 9, 2021 16:02 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantStock Option (Right to Buy) · Derivative	350,000	$0.00 Strike: $6.85	$0.00	Disclosure SEC source: 0001209191-21-063586 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-11-08 F1 · derivative.exercise_date: Twenty-five percent of the stock option shall be fully vested and exercisable on the first anniversary of the vesting commencement date, November 8, 2022, and the remaining seventy-five percent shall vest over the following three years in equal monthly installments. Read SEC document
June 02, 2021 Filed Jun 4, 2021 18:36 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $4.07	$0.00	Disclosure SEC source: 0001209191-21-038388 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 28, 2021 Filed Jun 2, 2021 19:04 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantOption (Right to Buy) · Derivative	25,000	Not disclosed Strike: $8.20	Not disclosed	Disclosure SEC source: 0001209191-21-037419 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2022, on the one year anniversary of the grant date. Read SEC document
May 04, 2021 Filed May 7, 2021 21:55 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	10,167	$0.00 Strike: $22.50	$0.00	Disclosure SEC source: 0001209191-21-031106 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document
May 04, 2021 Filed May 14, 2021 20:02 UTC Amendment	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	10,167	$0.00 Strike: $23.20	$0.00	Disclosure SEC source: 0001209191-21-032956 · doc4a.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_price: This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error. F2 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022. Read SEC document
September 24, 2020 Filed Sep 28, 2020 17:40 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-20-052242 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The option shall vest as to 1/36th of the total shares on October 24, 2020 and on each monthly anniversary thereafter such that the option shall be fully vested on September 24, 2023, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document
July 17, 2020 Filed Jul 21, 2020 19:37 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $11.37	Not disclosed	Disclosure SEC source: 0001209191-20-043248 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-07-16 F2 · price: Not applicable. F1 · derivative.exercise_date: This option grant will vest over three years in equal installments on the anniversary of the grant date. Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:47 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	10,167	$0.00 Strike: $20.59	$0.00	Disclosure SEC source: 0001209191-20-033322 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2030-05-27 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document
June 03, 2019 Filed Jun 5, 2019 17:22 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	10,167	$0.00 Strike: $11.84	$0.00	Disclosure SEC source: 0001209191-19-034842 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2029-06-02 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document
February 07, 2019 Filed Mar 29, 2019 16:21 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	5,907	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001209191-19-021736 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,907 Underlying: Common Stock · 5,907 shares Expires 2029-02-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerRestricted Stock Units · Derivative	199,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 14 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 199,000 shares Expires not disclosed F21 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F21 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F22 · derivative.exercise_date: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years. F18 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerRestricted Stock Units · Derivative	16,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 13 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires not disclosed F19 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F19 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F20 · derivative.exercise_date: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerRestricted Stock Units · Derivative	11,300	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 12 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,300 shares Expires not disclosed F16 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F16 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F17 · derivative.exercise_date: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	75,000	Not disclosed Strike: $3.99	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 11 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-09-18 F15 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F14 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	51,200	Not disclosed Strike: $4.64	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 10 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,200 shares Expires 2027-01-11 F13 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F12 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	50,000	Not disclosed Strike: $6.90	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 9 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-05-17 F11 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F10 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	41,667	Not disclosed Strike: $21.06	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 8 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,667 shares Expires 2023-09-24 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F9 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	16,667	Not disclosed Strike: $10.56	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 7 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2022-12-16 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	25,000	Not disclosed Strike: $10.44	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 6 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-12-12 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	8,334	Not disclosed Strike: $28.44	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 5 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,334 shares Expires 2020-12-12 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	8,334	Not disclosed Strike: $41.52	Not disclosed	Disclosure SEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 4 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8.334 shares Expires 2019-12-01 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.